Aardvark Therapeutics, Inc.
Moat Score — Aardvark Therapeutics, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Aardvark holds composition-of-matter and method-of-use patents around ARD-101 and its GFRAL mechanism, but as a pre-commercial company with no approved product, these assets remain unproven in the market. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a small clinical-stage biotech with no manufacturing or commercial scale, Aardvark has no cost advantage versus larger pharmaceutical competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved product generating revenue, Aardvark currently has no realized pricing power; any future pricing power depends entirely on clinical success and the competitive landscape at the time of approval. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Small-molecule pharmaceutical therapeutics like ARD-101 do not exhibit network effects. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | There are no established patients or physicians using ARD-101 yet, so meaningful switching costs do not currently exist; any future switching costs would depend on how entrenched a rival like Soleno's Vykat XR becomes first. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The Prader-Willi hyperphagia population is small enough that it may not support many competing branded therapies long-term, offering some efficient-scale protection if ARD-101 reaches approval, similar to the dynamic Soleno currently enjoys. |